News stories about RTI Surgical (NASDAQ:RTIX) have been trending very positive this week, Alpha One Sentiment reports. Alpha One, a unit of Accern, ranks the sentiment of press coverage by monitoring more than twenty million blog and news sources in real-time. Alpha One ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. RTI Surgical earned a media sentiment score of 0.56 on Alpha One’s scale. Alpha One also assigned news stories about the medical equipment provider an impact score of 71 out of 100, meaning that recent press coverage is likely to have an effect on the company’s share price in the next several days.
A number of research firms have weighed in on RTIX. Zacks Investment Research upgraded RTI Surgical from a “sell” rating to a “hold” rating in a research report on Thursday, May 11th. TheStreet upgraded RTI Surgical from a “d+” rating to a “c-” rating in a research report on Friday, May 5th.
Shares of RTI Surgical (NASDAQ:RTIX) opened at 4.85 on Friday. The firm has a 50-day moving average price of $4.23 and a 200-day moving average price of $3.54. RTI Surgical has a 52-week low of $2.50 and a 52-week high of $5.10. The firm’s market capitalization is $281.91 million.
RTI Surgical (NASDAQ:RTIX) last posted its quarterly earnings results on Thursday, April 27th. The medical equipment provider reported ($0.05) EPS for the quarter. The company had revenue of $69.90 million during the quarter, compared to analyst estimates of $67.68 million. RTI Surgical had a return on equity of 4.60% and a net margin of 0.24%. The company’s revenue for the quarter was up 3.7% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.03 earnings per share. On average, equities research analysts anticipate that RTI Surgical will post $0.08 EPS for the current year.
In other RTI Surgical news, CEO Camille Farhat acquired 61,693 shares of the company’s stock in a transaction on Thursday, May 18th. The shares were purchased at an average cost of $4.65 per share, with a total value of $286,872.45. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Nicholas J. Valeriani acquired 5,500 shares of the company’s stock in a transaction on Thursday, May 4th. The stock was acquired at an average cost of $4.60 per share, for a total transaction of $25,300.00. Following the completion of the purchase, the director now directly owns 25,770 shares of the company’s stock, valued at approximately $118,542. The disclosure for this purchase can be found here. Insiders acquired 122,023 shares of company stock valued at $552,321 over the last 90 days. Corporate insiders own 6.10% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was reported by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://transcriptdaily.com/2017/05/20/very-positive-media-coverage-likely-to-affect-rti-surgical-rtix-stock-price-updated-updated.html.
RTI Surgical Company Profile
RTI Surgical, Inc is engaged in producing orthopedic and other surgical implants that repair and promote the natural healing of human bone and other human tissues. The Company uses natural tissues, metals and synthetics process to produce its products. The Company’s business primarily consists of six categories, such as spine, sports medicine, ortho fixation, bone graft substitutes and general orthopedic (BGS and general orthopedic), dental and surgical specialties.
Receive News & Ratings for RTI Surgical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RTI Surgical Inc and related companies with MarketBeat.com's FREE daily email newsletter.